Sign inCreate account

Report workspace tools

NCT00066092COMPLETEDanonymous

Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.

Sponsor

Source record

Amgen

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Granulocyte Colony-Stimulating Factor (G-CSF) receptor, involved in the mobilization of peripheral blood progenitor cells (PBPC).

Indication / condition

AI-normalized

Lymphoma

Intervention

Source record

pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg

Source & freshness

Source record

NCT ID

NCT00066092

Original source

ClinicalTrials.gov

Source last updated

Feb 28, 2008

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00066092

Title

Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.

Sponsor

Amgen

Status

COMPLETED

Phase

Phase 2

Condition raw

Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology, Oncology

Condition normalized

Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology, Oncology

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Granulocyte Colony-Stimulating Factor (G-CSF) receptor, involved in the mobilization of peripheral blood progenitor cells (PBPC).

Target normalized

Granulocyte Colony-Stimulating Factor (G-CSF) receptor, involved in the mobilization of peripheral blood progenitor cells (PBPC).

Interventions

pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg

Public preview

Source record

This clinical trial, sponsored by Amgen, evaluates the efficacy and safety of pegfilgrastim compared to filgrastim for PBPC mobilization in patients with Hodgkin's and non-Hodgkin's lymphoma. Given the established market for G-CSF products, including filgrastim, pegfilgrastim's longer-acting formulation may provide a competitive advantage in terms of patient compliance and treatment convenience. The trial's completion in 2004 positions Amgen to leverage potential market exclusivity and enhance its portfolio in hematology and oncology, particularly in the context of autologous stem cell transplantation. The results could influence treatment guidelines and establish pegfilgrastim as a preferred option, impacting market dynamics and competitive positioning.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00066092

Status

COMPLETED

Phase

Phase 2

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Amgen, evaluates the efficacy and safety of pegfilgrastim compared to filgrastim for PBPC mobilization in patients with Hodgkin's and non-Hodgkin's lymphoma. Given the established market for G-CSF products, including filgrastim, pegfilgrastim's longer-acting formulation may provide a competitive advantage in terms of patient compliance and treatment convenience. The trial's completion in 2004 positions Amgen to leverage potential market exclusivity and enhance its portfolio in hematology and oncology, particularly in the context of autologous stem cell transplantation. The results could influence treatment guidelines and establish pegfilgrastim as a preferred option, impacting market dynamics and competitive positioning.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 28, 2008
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00066092

Indication

Lymphoma

Modality

small molecule

Target

Granulocyte Colony-Stimulating Factor (G-CSF) receptor, involved in the mobilization of peripheral blood progenitor cells (PBPC).

Intervention

pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.